---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-046755"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-10-13T13:23:00+00:00"
generated_at: "2026-10-13T13:24:11.082411+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# bioAffinity to present CHEST 2026 data on sputum tests for asthma and COPD lung inflammation

## Summary
- bioAffinity will present poster 3071 at CHEST 2026 on Oct. 20 in Phoenix on sputum-based tests measuring lung inflammation in asthma and COPD.
- Research measured targets TSLP, CRLF2, IL4-Rα (CD124) and IL-5, linked to drugs tezepelumab, verkitug, dupilumab and mepolizumab.
- Sputum samples came from people with asthma, smokers with/without COPD, a smoker with both COPD and asthma, and healthy individuals; flow cytometry, ELISA and machine learning were used.
- CyPath Lung, marketed as an LDT, showed 92% sensitivity, 87% specificity, 88% accuracy and 99% NPV for lung cancer in high-risk patients with nodules under 20 mm.
- Global asthma therapeutics market was about $29.7 billion in 2025 and is projected to reach $47.6 billion by 2034.

## SEC filing metadata
- accession: 0001493152-26-046755
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-10-13T13:23:00+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226046755/0001493152-26-046755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226046755/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-046755
- JSON: https://secwatch.observer/filing/0001493152-26-046755.json
- Plain text: https://secwatch.observer/filing/0001493152-26-046755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.